Intent to Sole Source - Preventative Maintenance Agreement for 4 Apheresis Machines (Optias) NOI-OLAO-CC-26-005158
Summary
AI-generated · Apr 30, 2026Provide a one-year service maintenance agreement for the NIH Clinical Center’s apheresis machines (Optias) used to perform extracorporeal blood component separation for donors and patients, with options to extend for two additional one-year periods. The maintenance must come from the original equipment manufacturer’s provider (Terumo BCT) and cover equipment used in patient care, aligned with FDA and AABB standards.
This is a sole-source action under FAR 6.302-1; no competitive solicitation will be issued. Capable, responsible sources may submit capability statements for consideration, but the award will be made to Terumo BCT based on the justification for other than full and open competition.
This is a Notice of Intent, not a request for proposal. The National Institute of Health, Clinical Center (NIH-CC) intends to negotiate on an other than full and open competition basis with the following vendor: Terumo BCT. Acquisition Descripton: The National Institutes of Health, Office of Purchasing and Contracts on behalf of Clinical Center (CC), Blood Services Section (BSS) has a need to approve a "Justification for Other Than Full and Open" requirement in accordance with FAR 8.3, Other Than Full and Open Competition. This procurement action in accordance with IAW FAR 6.302-1 is based on the need to procure a service agreement for our apheresis machines which are used in a patient care capacity. Service Agreement is for a one-year period with the two option years. Approval of this purchase is for service agreement for a specific type of instrument which is used to separate blood and blood products on donors and patients in the NIH Clinical Center. The DTM is a unique blood center which collects blood and blood components from healthy donors for patients participating in many protocols. However, blood and blood products are also withdrawn from patients when prescribed by a physician, which may have a therapeutic benefit to treat their medical condition. These two (2) apheresis machines are used to perform extracorporeal therapy in which the blood of donors or patients is passed through the device to separate blood components. Numerous regulatory authorities, specifically the Food and Drug Administration (FDA) and AABB set policy and enforce this policy for care and maintenance of equipment that is used, in support of donors and patients per the above. The statutory authority for this sole source requirement is 41 U.S.C. 253(c) (1) as implemented by FAR 6.302-1 only one responsible source and no other supply of service will satisfy agency requirements. THIS IS NOT A REQUEST FOR PROPOSAL. All responsible sources that could provide the required may submit a capability statement that will be considered by email (subject line to reference NOI-OLAO-CC-26-005158) by 12:00 PM eastern standard time on 05/13/2026 to: valerie.gregorio@nih.gov. All responses received by the closing date of this synopsis will be considered by the Government. A determination not to compete this requirement, based upon responses to this notice, is solely within the discretion of the Government.
From Special Notice posted on Apr 29, 2026Notice history
1Details
Award Information
Not yet awarded
Agency
Place of Performance
USA